1856. ReadyVax: A New Mobile Vaccine Information App
Session: Poster Abstract Session: Vaccines: Improving Immunization Uptake
Saturday, October 10, 2015
Room: Poster Hall
Background: Vaccine information of varying quality is widely available through many different sources. It is important for individuals to have access to a trustworthy, evidence-based source of vaccine information, both for routinely recommended vaccines and vaccines that may be used in the event of public health emergencies (e.g., influenza pandemic). To address these information needs, we have developed a new mobile smartphone app, ReadyVax.

Methods: Through our multi-disciplinary team of vaccine and communications experts, we developed evidence-based information summaries on all vaccines recommended for routine use in the United States and each disease preventable by vaccination. We developed answers to frequently asked questions about vaccines and vaccination. Through our technology partner, we developed ReadyVax in a manner to provide clear and easy access to all of this information. Information is presented through expandable fields in four core screens (Vaccines, Diseases, Common Questions, and Resources). ReadyVax was deployed for use on iOS devices. Information complexity is tailored for different user types, including healthcare providers and patients/parents. As new information is updated into ReadyVax and accessed, it is stored on the user’s device, allowing access even when there is no network connectivity.

Results: ReadyVax was made available in the Apple App Store on January 12, 2015. By May 27, 2015, ReadyVax has been downloaded by 1,123 unique users, who have spent an average of one minute thirteen second perusing information in the app. There have been 3,628 unique screen views, an average of 2.6 screens/user session. ReadyVax has been downloaded by users in 57 different countries; most users (61.5%) are from the United States. 

Conclusion: ReadyVax presents an opportunity to provide evidence-based information about vaccines and vaccination for routine use. We are continuing outreach efforts to public health partners to facilitate dissemination of ReadyVax. Continued use of ReadyVax can establish it as a trusted source of information, increasing the likelihood that in the event of a public health emergency, ReadyVax will serve as the main source of information dissemination with regard to vaccines in the emergency.

Robert Bednarczyk, PhD1,2, Paula Frew, PhD, MPH, MA3, Daniel Salmon, PhD, MPH4, Ellen Whitney, MPH5 and Saad Omer, MBBS, MPH, PhD, FIDSA2, (1)Departments of Global Health and Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, (2)Emory Vaccine Center, Atlanta, GA, (3)School of Medicine, Emory University, Decatur, GA, (4)Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, (5)Rollins School of Public Health, Emory University, Atlanta, GA


R. Bednarczyk, None

P. Frew, None

D. Salmon, None

E. Whitney, None

S. Omer, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.